Adicet Bio amasses $80 mln Series B
Menlo Park, California-based Adicet Bio Inc, a biopharmaceutical company, has raised $80 million in Series B financing. The investors include aMoon2 Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC Inc, Samsung Venture Investment Corporation, OrbiMed, Novartis Venture Fund and Pontifax.
3 October 2019•1 min read
